Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
6(75.0%)
Phase 1
2(25.0%)
8Total
Phase 2(6)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07446049Phase 2Not Yet Recruiting

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

Role: lead

NCT07157956Phase 1Not Yet Recruiting

CVL006 Combination Therapy in Advanced Solid Tumors

Role: lead

NCT06621615Phase 1Not Yet Recruiting

Clinical Study of CVL006 Injection in Advanced Solid Tumors

Role: lead

NCT06519110Phase 2Not Yet Recruiting

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations

Role: lead

NCT06374888Phase 2Not Yet Recruiting

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Role: lead

NCT06293716Phase 2Not Yet Recruiting

CVL237 Tablets for APDS/PASLI

Role: lead

NCT06183736Phase 2Not Yet Recruiting

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Role: lead

NCT06029816Phase 2Unknown

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

Role: lead

All 8 trials loaded